N. K. Mazina & P. V. Mazin. (2017). Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients. IRBIS LLC.
Chicago Style (17th ed.) CitationN. K. Mazina and P. V. Mazin. Comparative Pharmaco-economic Analysis of Using Enzalutamide, Abiraterone and Cabazitaxel in Post-docetaxel Castration-resistant Prostate Cancer Patients. IRBIS LLC, 2017.
MLA (9th ed.) CitationN. K. Mazina and P. V. Mazin. Comparative Pharmaco-economic Analysis of Using Enzalutamide, Abiraterone and Cabazitaxel in Post-docetaxel Castration-resistant Prostate Cancer Patients. IRBIS LLC, 2017.
Warning: These citations may not always be 100% accurate.